These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17206943)

  • 1. Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis.
    Rautiainen H; Färkkilä M; Neuvonen M; Sane T; Karvonen AL; Nurmi H; Kärkkäinen P; Neuvonen PJ; Backman JT
    Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1545-52. PubMed ID: 17206943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
    Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis.
    Hempfling W; Grunhage F; Dilger K; Reichel C; Beuers U; Sauerbruch T
    Hepatology; 2003 Jul; 38(1):196-202. PubMed ID: 12830002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial.
    Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Pikkarainen P; Nuutinen H; Färkkilä M
    Hepatology; 2005 Apr; 41(4):747-52. PubMed ID: 15754377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy.
    Cino M; Greenberg GR
    Am J Gastroenterol; 2002 Apr; 97(4):915-21. PubMed ID: 12003427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?
    Lindor KD; Janes CH; Crippin JS; Jorgensen RA; Dickson ER
    Hepatology; 1995 Feb; 21(2):389-92. PubMed ID: 7843710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis.
    Floreani A; Carderi I; Ferrara F; Rizzotto ER; Luisetto G; Camozzi V; Baldo V
    Dig Liver Dis; 2007 Jun; 39(6):544-8. PubMed ID: 17416215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study.
    Levy C; Harnois DM; Angulo P; Jorgensen R; Lindor KD
    Liver Int; 2005 Feb; 25(1):117-21. PubMed ID: 15698408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.
    Chan CW; Gunsar F; Feudjo M; Rigamonti C; Vlachogiannakos J; Carpenter JR; Burroughs AK
    Aliment Pharmacol Ther; 2005 Feb; 21(3):217-26. PubMed ID: 15691295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis.
    Dilger K; Cascorbi I; Grünhage F; Hohenester S; Sauerbruch T; Beuers U
    Liver Int; 2006 Apr; 26(3):285-90. PubMed ID: 16584389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis.
    Dimoulios P; Kolios G; Notas G; Matrella E; Xidakis C; Koulentaki M; Tsagarakis N; Kouroumalis A; Kouroumalis E
    Aliment Pharmacol Ther; 2005 Feb; 21(3):227-34. PubMed ID: 15691296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis.
    Menon KV; Angulo P; Boe GM; Lindor KD
    Am J Gastroenterol; 2003 Apr; 98(4):889-92. PubMed ID: 12738473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
    Babatin MA; Sanai FM; Swain MG
    Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis.
    Dilger K; Denk A; Heeg MH; Beuers U
    Hepatology; 2005 Mar; 41(3):595-602. PubMed ID: 15726657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis.
    Camisasca M; Crosignani A; Battezzati PM; Albisetti W; Grandinetti G; Pietrogrande L; Biffi A; Zuin M; Podda M
    Hepatology; 1994 Sep; 20(3):633-7. PubMed ID: 8076921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study.
    Benetti A; Crosignani A; Varenna M; Giussani CS; Allocca M; Zuin M; Podda M; Battezzati PM
    J Clin Gastroenterol; 2008 Mar; 42(3):306-11. PubMed ID: 18223492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of vibration therapy on bone mineral density in postmenopausal women with osteoporosis.
    Ruan XY; Jin FY; Liu YL; Peng ZL; Sun YG
    Chin Med J (Engl); 2008 Jul; 121(13):1155-8. PubMed ID: 18710630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy.
    Legroux-Gerot I; Vignau J; Collier F; Cortet B
    Calcif Tissue Int; 2008 Nov; 83(5):315-23. PubMed ID: 18836675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.